Tawam Hospital
Neurology

Author Of 1 Presentation

Observational Studies Poster Presentation

P0866 - Disease-Modifying Therapy of Multiple Sclerosis with Ocrelizumab: a two years experience of MS Clinic in the Eastern Region of Abu Dhabi Emirate, UAE (ID 460)

Speakers
Presentation Number
P0866
Presentation Topic
Observational Studies

Abstract

Background

Background:

The prevalence of multiple sclerosis (MS) in Abu Dhabi Emirati population had been reported to be one of the highest on the Arab peninsula. The Ocrelizumab (OC) approved for treatment of a broad spectrum MS sub-types including relapsing-remitting, active secondary progressive, primary progressive disease

Objectives

Objectives:

To assess the Ocrelizumab disease modifying therapy (DMT) efficacy and safety in cohort of MS patients treated in the Eastern region of Abu Dhabi Emirate

Methods

Methods:

Retrospective charts review of MS patients treated with OC at our MS clinic, Tawam hospital from January 2018 till June 2020

Results

Results:

We retrospectively reviewed the course of 20 patients with MS who received OC. The average age of patients was 32 years (19 to 52 years), female/male ratio was 1:1. All patients had a high hyperintense lesions load before OC initiation. It was no clinical relapses on OC treatment, but before OC treatment annual relapse rate was 0.625. One patient showed radiological activity, while the other one had a clinical and radiological relapse diagnosed in the first two weeks since the onset of OC treatment . The majority of MS patients (84.2% ) had no disease activity or disease progression during the OC treatment period. Before OC treatment three MS patients were naive, but the rest of them previously received from one to four DMTs indicating the complicated course and long history of the disease. Ten patients previously were on Natalizumab, 11 were on oral DMTs, 1 was on Rituximab, and one on Mitoxantrone. JCV was positive in 11 patients who were started on OC. The average treatment duration with OC was 16-months, average given doses were 2.6 Eighteen patients were adherent to the treatment, and had regular follow up. The average baseline EDSS before OC treatment was 2.32 (ranging from 0 to 7), while on OC DMT average EDSS became 2.14. Among all patients with MS treated by OC, only one patient had a mild infusion reaction over the observation period. They were no cases of PML in patients who were switched from Natalizumab to OC. During COVID -19 out brake OC regular infusion was postponed for approximately 6 weeks, but none of the patients had a clinical relapse in that time or COVID infection.

Conclusions

Conclusion:

DMT of Multiple sclerosis with Ocrelizumab showed good control of disease activity and the absence of disease progression in our cohort of patients over more than 2.0 years since the onset of treatment. The Ocrelizumab is efficient, feasible and safe DMT for different MS sub-types

Collapse

Presenter Of 1 Presentation

Observational Studies Poster Presentation

P0866 - Disease-Modifying Therapy of Multiple Sclerosis with Ocrelizumab: a two years experience of MS Clinic in the Eastern Region of Abu Dhabi Emirate, UAE (ID 460)

Speakers
Presentation Number
P0866
Presentation Topic
Observational Studies

Abstract

Background

Background:

The prevalence of multiple sclerosis (MS) in Abu Dhabi Emirati population had been reported to be one of the highest on the Arab peninsula. The Ocrelizumab (OC) approved for treatment of a broad spectrum MS sub-types including relapsing-remitting, active secondary progressive, primary progressive disease

Objectives

Objectives:

To assess the Ocrelizumab disease modifying therapy (DMT) efficacy and safety in cohort of MS patients treated in the Eastern region of Abu Dhabi Emirate

Methods

Methods:

Retrospective charts review of MS patients treated with OC at our MS clinic, Tawam hospital from January 2018 till June 2020

Results

Results:

We retrospectively reviewed the course of 20 patients with MS who received OC. The average age of patients was 32 years (19 to 52 years), female/male ratio was 1:1. All patients had a high hyperintense lesions load before OC initiation. It was no clinical relapses on OC treatment, but before OC treatment annual relapse rate was 0.625. One patient showed radiological activity, while the other one had a clinical and radiological relapse diagnosed in the first two weeks since the onset of OC treatment . The majority of MS patients (84.2% ) had no disease activity or disease progression during the OC treatment period. Before OC treatment three MS patients were naive, but the rest of them previously received from one to four DMTs indicating the complicated course and long history of the disease. Ten patients previously were on Natalizumab, 11 were on oral DMTs, 1 was on Rituximab, and one on Mitoxantrone. JCV was positive in 11 patients who were started on OC. The average treatment duration with OC was 16-months, average given doses were 2.6 Eighteen patients were adherent to the treatment, and had regular follow up. The average baseline EDSS before OC treatment was 2.32 (ranging from 0 to 7), while on OC DMT average EDSS became 2.14. Among all patients with MS treated by OC, only one patient had a mild infusion reaction over the observation period. They were no cases of PML in patients who were switched from Natalizumab to OC. During COVID -19 out brake OC regular infusion was postponed for approximately 6 weeks, but none of the patients had a clinical relapse in that time or COVID infection.

Conclusions

Conclusion:

DMT of Multiple sclerosis with Ocrelizumab showed good control of disease activity and the absence of disease progression in our cohort of patients over more than 2.0 years since the onset of treatment. The Ocrelizumab is efficient, feasible and safe DMT for different MS sub-types

Collapse